Pipeline Analysis
1.NRX100:
IV Ketamine, treat acute suicidality, applied for accelerated approval in 2024 (need an estimate) FYI: nasal ketamine is approved and sold under SPRAVATO® by Janssen. Here Janssen used a chiral isomer of ketamine called esketamine for depression
Planned spin-out and term sheet in hand
3.5 million of targeting patients;
Formulation is unique (concentration and alteration to limit abuse) Give caregiver a more legit way to prescribe ketamine (off-label problem)
2.NRX101
A fixed dose of DCS+ Lurasidone
D-cycloserine (short for DCS, NMDAR glycine site inhibitor) , found to have potential to treat depression but discouraged due to CNS side effects. Company’s CSO patented the use of DCS along with serotonergic drug to treat depression that can lessen side effects
Lurasidone is a marketed serotonergic drug.
Defined as an adjunctive medication for NRX100, used after IV ketamine. Current in Ph 2b/3 study enrollment for suicidal dipolar depression;
Phase 2a for chronic pain. Partenering with Alvogen (a generic drug company); Will cover cost if good readouts
Phase 2 data published in IJBD(IF:4.0): 22 patients, only 11 completed, data is limited and seems not impressive![]()
Above are all clinical assets NRXP holds. Feel free to leave a comment to share your thoughts about this company![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
